HUP9801575A2 - 1,3-Dihidro-1-(fenil-alkil)-2H-imidazol-2-on származékok alkalmazása PDE IV és citokin hatású gyógyszerkészítmények előállítására, új 1,3-dihidro-1-(fenil-alkil)-2H-imidazol-2-on-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmé.. - Google Patents
1,3-Dihidro-1-(fenil-alkil)-2H-imidazol-2-on származékok alkalmazása PDE IV és citokin hatású gyógyszerkészítmények előállítására, új 1,3-dihidro-1-(fenil-alkil)-2H-imidazol-2-on-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmé..Info
- Publication number
- HUP9801575A2 HUP9801575A2 HU9801575A HUP9801575A HUP9801575A2 HU P9801575 A2 HUP9801575 A2 HU P9801575A2 HU 9801575 A HU9801575 A HU 9801575A HU P9801575 A HUP9801575 A HU P9801575A HU P9801575 A2 HUP9801575 A2 HU P9801575A2
- Authority
- HU
- Hungary
- Prior art keywords
- carbon
- groups
- alkyl
- substituted
- sulfonyl
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 10
- -1 indanyl- Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 239000000843 powder Substances 0.000 abstract 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical class 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 230000009852 coagulant defect Effects 0.000 abstract 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 abstract 1
- 239000004062 cytokinin Substances 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány (I) általánős képletű vegyületek, N-őxidjaik,gyógyszerészetileg alkalmazható savval vagy bázissal alkőtőtt addícióssóik és sztereőkémiai izőmer alakjaik alkalmazására vőnatkőzik, őlyangyógyszerek előállítására, amelyekkel a főszfődiészteráz IV (PDE IV)abnőrmális enzimes vagy katalitikűs aktivitásával kapcsőlatősbetegségben vagy fiziőlógiailag kárős citőkin felesleggel kapcsőlatősbetegségekben, elsősőrban allergiás, atópiás és gyűlladásősbetegségekben szenvedő melegvérű állatők kezelésére lehet használni.Az (I) általánős képletben R1 és R2 jelentése egymástól függetlenülhidrőgénatőm, 1-6 szénatőmős alkil-, diflűőr-metil-, triflűőr-metil-,3-6 szénatőmős ciklőalkil-, az őxigén-, kén- vagy nitrőgénatőm közülegy vagy két heterőatőmőt tartalmazó telített 5-, 6- vagy 7-tagúheterőciklűsős csőpőrt, indanil-, bicik- lő[2,2,1]-2-heptenil-,biciklő[2,2,1]-heptanil-, 1-6 szénatőmős alkil-szűlfőnil-, aril-szűlfőnil-, vagy szűbsztitűált 1-10 szénatőmős alkilcsőpőrt, R3jelentése hidrőgén- vagy halőgénatőm, vagy 1-6 szénatőmősalkőxicsőpőrt, R4 jelentése hidrőgén- vagy halőgénatőm, vagy adőttesetben szűbsztitűált 1-6 szénatőmős alkilcsőpőrt, triflűőr-metil-csőpőrt, 3-6 szénatőmős ciklőalkil-, karbőxil-, 1-4 szénatőmős alkőxi-karbőnil-, 3-6 szénatőmős ciklőalkil-aminő-karbőnil-, aril- vagy Het1csőpőrt, vagy R4 jelentése egy -O-R6 vagy -NH-R7 általánős képletűcsőpőrt, R5 jelentése hidrőgén- vagy halőgénatőm, hidrőxil- vagy 2-6szénatőmős alkilcsőpőrt, vagy R4 és R5 együtt egy kétértékű csőpőrtőtalkőt, amely lehet -(CH2)n-, -CH2-CH2-O-CH2-CH2-, -CH2-CH2-N(R8)-CH2-CH2- vagy -CH2-CH=CH-CH2- csőpőrt, Y jelentése vegyértékkötés,halőgén(1-4 szénatőmős alkán-diil)- vagy 1-4 szénatőmős alkán-diil-cőspőrt, -A-B- jelentése -CR9=CR10- vagy -CHR9-CHR10 általánős képletűcsőpőrt, és L jelentése hidrőgénatőm, adőtt esetben szűbsztitűált 1-6szénatőmős alkilcsőpőrt, 1-6 szénatőmős alkil-karbőnil-, 1-6szénatőmős alkőxi-karbőnil-csőpőrt, adőtt esetben szűbsztitűált 3-6szénatőmős alkenilcsőpőrt, adőtt esetben szűbsztitűáltpiperidinilcsőpőrt, 1-6 szénatőmős alkil-szűlfőnil- vagy aril-szűlfőnil-csőpőrt, aril jelentése adőtt esetben szűbsztitűáltfenilcsőpőrt, Het1 jelentése mőrfőlinil- vagy adőtt esetbenszűbsztitűált piridinil-, fűranil-, tienil-, hidrőxi-piridinil-,imidazőlil-, -tiazőlil-, őxazőlil-, izőkinilinil-, -kinőlinőnil-, -piperidinil- vagy -piperazinil-csőpőrt. A találmány új PDE IV és citőkingátló hatású vegyületekre, ezekelőállítására szőlgáló eljárásra és az új vegyületeket tartalmazógyógyszerkészítményekre is vőnatkőzik. ŕ
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95200868 | 1995-04-06 | ||
| EP95202898 | 1995-10-26 | ||
| PCT/EP1996/001394 WO1996031485A1 (en) | 1995-04-06 | 1996-03-28 | 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP9801575A2 true HUP9801575A2 (hu) | 1999-01-28 |
| HUP9801575A3 HUP9801575A3 (en) | 1999-03-01 |
| HU223324B1 HU223324B1 (hu) | 2004-06-28 |
Family
ID=26139205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9801575A HU223324B1 (hu) | 1995-04-06 | 1996-03-28 | 1,3-Dihidro-1-(fenil-alkil)-2H-imidazol-2-on származékok alkalmazása PDE IV és citokin hatású gyógyszerkészítmények előállítására, új 1,3-dihidro-1-(fenil-alkil)-2H-imidazol-2-on-származékok, eljárás előállításukra és ezeket tartalmazó ... |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5994376A (hu) |
| EP (1) | EP0819122B1 (hu) |
| JP (1) | JP4562101B2 (hu) |
| KR (1) | KR100406628B1 (hu) |
| CN (1) | CN1068591C (hu) |
| AR (1) | AR002732A1 (hu) |
| AT (1) | ATE214052T1 (hu) |
| AU (1) | AU702947B2 (hu) |
| CA (1) | CA2216653C (hu) |
| CY (1) | CY2328B1 (hu) |
| CZ (1) | CZ293127B6 (hu) |
| DE (1) | DE69619661T2 (hu) |
| DK (1) | DK0819122T3 (hu) |
| ES (1) | ES2174064T3 (hu) |
| HK (1) | HK1007880A1 (hu) |
| HR (1) | HRP960155A2 (hu) |
| HU (1) | HU223324B1 (hu) |
| IL (1) | IL117807A (hu) |
| MX (1) | MX9707652A (hu) |
| MY (1) | MY119254A (hu) |
| NO (1) | NO314339B1 (hu) |
| NZ (1) | NZ304877A (hu) |
| PL (1) | PL187375B1 (hu) |
| PT (1) | PT819122E (hu) |
| SI (1) | SI0819122T1 (hu) |
| TW (1) | TW332201B (hu) |
| WO (1) | WO1996031485A1 (hu) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
| CZ297474B6 (cs) * | 1996-10-02 | 2006-12-13 | Janssen Pharmaceutica N. V. | Deriváty 2-kyaniminoimidazolu inhibující PDE IV |
| PL337875A1 (en) * | 1997-07-10 | 2000-09-11 | Janssen Pharmaceutica Nv | Derivatives of 6-azauracil as il-5 inhibitors |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| UA66842C2 (uk) * | 1998-04-01 | 2004-06-15 | Янссен Фармацевтика Н.В. | Похідні піридину як інгібітори pde iv |
| US6172118B1 (en) * | 1998-04-14 | 2001-01-09 | Smithkline Beecham Corporation | Compounds |
| EP1071645A4 (en) * | 1998-04-14 | 2003-04-02 | Smithkline Beecham Corp | COMPOUNDS INHIBITING ISOENZYME PHOSPHODIESTERASE 4 (PDE 4) |
| US6498158B1 (en) | 1998-11-23 | 2002-12-24 | Janssen Pharmaceutica N.V. | Il-5 inhibiting 6-azauracil derivatives |
| UA73107C2 (en) | 1998-12-18 | 2005-06-15 | Janssen Pharmaceutica Nv | Derivatives of 6-azaurcyle inhibiting il-5 |
| EP1322310A4 (en) * | 2000-09-13 | 2004-09-15 | Merck & Co Inc | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS |
| JP4510384B2 (ja) * | 2001-05-23 | 2010-07-21 | 田辺三菱製薬株式会社 | 骨折治癒促進用組成物 |
| JP4510383B2 (ja) | 2001-05-23 | 2010-07-21 | 田辺三菱製薬株式会社 | 軟骨疾患修復治療用組成物 |
| US6706739B2 (en) * | 2001-08-21 | 2004-03-16 | National Health Research Institute | Imidazolidinone compounds |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| GB0326407D0 (en) * | 2003-11-12 | 2003-12-17 | Glaxo Group Ltd | Chemical compounds |
| GB0412865D0 (en) * | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| JP4657297B2 (ja) * | 2004-07-05 | 2011-03-23 | ドン ファ ファーマシューティカル カンパニー リミテッド | アレルギー性炎症疾患の予防及び治療用組成物 |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| US8354434B2 (en) * | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
| US7674811B2 (en) | 2006-03-14 | 2010-03-09 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| US7390772B2 (en) * | 2006-05-18 | 2008-06-24 | International Flavor & Fragrances Inc. | 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations |
| EP2155226A4 (en) * | 2007-06-14 | 2010-07-28 | Univ California | COMPOUNDS FOR INHIBITING AGGREGATION OF PROTEINS AND METHODS OF MAKING AND USING SAME |
| US8343970B2 (en) | 2010-03-12 | 2013-01-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| EP3285760A4 (en) | 2015-04-24 | 2018-09-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Ｐｄｅ１０阻害剤の固体状態形態 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL285394A (hu) * | 1961-11-17 | |||
| US3184060A (en) | 1963-02-13 | 1965-05-18 | Owens Illinois Glass Co | Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials |
| AU9030691A (en) * | 1990-11-06 | 1992-05-26 | Smithkline Beecham Corporation | Imidazolidinone compounds |
| DK0672031T3 (da) * | 1992-12-02 | 2003-06-10 | Pfizer | Catecholdiethere som selektive PDE IV-inhibitorer |
| TW263495B (hu) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
-
1996
- 1996-03-22 TW TW085103447A patent/TW332201B/zh not_active IP Right Cessation
- 1996-03-28 SI SI9630434T patent/SI0819122T1/xx unknown
- 1996-03-28 NZ NZ304877A patent/NZ304877A/en not_active IP Right Cessation
- 1996-03-28 CZ CZ19973149A patent/CZ293127B6/cs not_active IP Right Cessation
- 1996-03-28 MX MX9707652A patent/MX9707652A/es unknown
- 1996-03-28 DE DE69619661T patent/DE69619661T2/de not_active Expired - Lifetime
- 1996-03-28 JP JP52995996A patent/JP4562101B2/ja not_active Expired - Lifetime
- 1996-03-28 AU AU52755/96A patent/AU702947B2/en not_active Expired
- 1996-03-28 CN CN96193101A patent/CN1068591C/zh not_active Expired - Lifetime
- 1996-03-28 US US08/930,296 patent/US5994376A/en not_active Expired - Lifetime
- 1996-03-28 CA CA002216653A patent/CA2216653C/en not_active Expired - Lifetime
- 1996-03-28 ES ES96909150T patent/ES2174064T3/es not_active Expired - Lifetime
- 1996-03-28 WO PCT/EP1996/001394 patent/WO1996031485A1/en active IP Right Grant
- 1996-03-28 AT AT96909150T patent/ATE214052T1/de active
- 1996-03-28 KR KR1019970706853A patent/KR100406628B1/ko not_active IP Right Cessation
- 1996-03-28 PT PT96909150T patent/PT819122E/pt unknown
- 1996-03-28 HU HU9801575A patent/HU223324B1/hu active IP Right Grant
- 1996-03-28 EP EP96909150A patent/EP0819122B1/en not_active Expired - Lifetime
- 1996-03-28 DK DK96909150T patent/DK0819122T3/da active
- 1996-03-28 PL PL96322654A patent/PL187375B1/pl unknown
- 1996-04-02 HR HR95202898.3A patent/HRP960155A2/hr not_active Application Discontinuation
- 1996-04-03 AR ARP960102076A patent/AR002732A1/es active IP Right Grant
- 1996-04-03 IL IL11780796A patent/IL117807A/en not_active IP Right Cessation
- 1996-04-05 MY MYPI96001300A patent/MY119254A/en unknown
-
1997
- 1997-10-06 NO NO19974602A patent/NO314339B1/no not_active IP Right Cessation
-
1998
- 1998-07-07 HK HK98108913A patent/HK1007880A1/xx not_active IP Right Cessation
-
1999
- 1999-07-27 US US09/362,007 patent/US6403805B1/en not_active Expired - Lifetime
-
2002
- 2002-07-15 CY CY0200043A patent/CY2328B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9801575A2 (hu) | 1,3-Dihidro-1-(fenil-alkil)-2H-imidazol-2-on származékok alkalmazása PDE IV és citokin hatású gyógyszerkészítmények előállítására, új 1,3-dihidro-1-(fenil-alkil)-2H-imidazol-2-on-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmé.. | |
| TR200100300T2 (tr) | Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri | |
| HUP9802323A2 (hu) | Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények | |
| HUP0203897A2 (hu) | VLA-4-től függő sejtadhéziót gátló nempeptid inhibitor vegyületek, valamint ezeket tartalmazó gyógyászati készítmények gyulladásos-, autoimmun- és légzőszervi betegségek kezelésére | |
| HUP9802702A2 (hu) | A Her-2 receptort szelektíven gátló aril- és heteroaril-kinazolinok alkalmazása gyógyszerkészítmények előállítására, az új vegyületek és az azokat tartalmazó gyógyszerkészítmények | |
| KR910016744A (ko) | N-(4-피페리디닐)(디하이드로벤조푸란 또는 디하이드로-2h-벤조피란)카르복스아미드 유도체 | |
| HUT52058A (en) | Process for producing n-substituted nicotinamide derivatives | |
| EP2590981B1 (en) | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| BR9914379A (pt) | Composto, processo para a preparação de um composto, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| ES2001936A6 (es) | Procedimiento para la preparacion de indoles sustituidos con heterociclos. | |
| TNSN05252A1 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them | |
| RU2002125860A (ru) | Новые производные циклического амида | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0000658A2 (hu) | Szulfonamidszármazékok, eljárás előállításukra és gyógyszerként való alkalmazásuk | |
| HUT50163A (en) | Process for production of derivatives of indole and medical compositions containing them as active substance | |
| US20080318943A1 (en) | Compounds and Uses Thereof - 848 | |
| ES2142861T3 (es) | Derivados de 4-(1h-2-metilimidazo(4,5-c)piridinilmetil)fenilsulfonamida como antagonistas del paf. | |
| IE872650L (en) | Imidazopyridine derivatives, their production, and¹pharmaceutical compositions containing them | |
| HUT54149A (en) | Process for producing new 3-brackets open 4-(1-substituted-4-piperazinyl)-butyl brackets closed-4-thiazolidinone derivatives and pharmaceutical compositions comprising such compounds | |
| HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| HUP9904032A2 (hu) | 1,2,4-Benzotiadiazin-származékok,valamint ezeket tartalmazó gyógyászati készítmények | |
| JP2021506805A (ja) | 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| RU2297420C2 (ru) | Средство против кислотоустойчивых бактерий, содержащее гетероциклические производные бензоксазина в качестве активного компонента | |
| HUP9700708A2 (hu) | N-[(9-pirimido[1,2-a]indolil)-metil-fenil-acetil]-fenil-glicinol-származékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és intermedierjeik | |
| HUP0201315A2 (hu) | 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HFG4 | Patent granted, date of granting |
Effective date: 20040419 |